Remote Patient Monitoring in Myeloma: How Technology Is Transforming Bispecific Antibody Management

In 'Remote Patient Monitoring in Myeloma: How Technology Is Transforming Bispecific Antibody Management,' our panel of experts delve into the following critical question:

Remote monitoring has emerged as a tool to support patients. How does that work in practice, and who is doing this in your practice?

Led by the moderator, the panelists examined how remote patient monitoring is being implemented in community oncology settings to support patients receiving bispecific antibody therapy, with one panelist describing their early-stage program, funded through a state cancer innovation grant, that deploys wearable monitoring devices to all new patients undergoing step-up dosing as well as maintenance patients deemed at elevated risk for infection or complications by their provider. The discussion highlighted how a 24/7 remote nurse navigation team actively monitors patient data in real time, enabling proactive outreach when abnormal readings are detected and allowing clinicians to distinguish between clinically significant alerts that require immediate intervention and those that can safely be addressed at the next clinical encounter, reducing unnecessary after-hours emergency department visits while maintaining patient safety. The panelists also explored the transformative potential of remote monitoring as a pathway toward fully outpatient bispecific antibody step-up dosing for appropriate patients, noting that by combining continuous vital sign surveillance with pre-established hospital partnership agreements for after-hours triage, community oncology practices without inpatient capabilities or weekend hours can now confidently extend the reach of these powerful therapies to patients who would otherwise require extended stays at academic centers.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'Navigating REMS: Challenges, Perspectives, and the Path Forward for Bispecific Antibody Programs,' features the panelists advancing their conversation on multiple myeloma and focusing on where the operational friction around REMS requirements and step-up dosing logistics truly lives in practice.